Retia Medical Raises $15 Million To Accelerate Commercialization Of The Argos Hemodynamic Monitor

Retia Medical, an innovator in advanced hemodynamic monitoring, today announced that it has secured $15 million in Series B funding. The financing round was led by Fresenius Medical Care Ventures with participation from a second strategic investor, Red Cedar Ventures, and existing investor, the Pritzker-Vlock Family Office. Retia Medical will use the funding to expand its commercial team and accelerate the development of its next-generation algorithms for guiding care for high-risk patients.